Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.

Annals of the Rheumatic Diseases
C A WijbrandtsP P Tak

Abstract

Macrophage migration inhibitory factor (MIF) has recently emerged as an important cytokine possibly linking rheumatoid arthritis (RA) and atherogenesis. Because atherogenesis is accelerated in RA this study was conducted to investigate whether anti-tumour necrosis factor (TNF) therapy could lead to sustained downregulation of systemic MIF levels and improvement in lipid profiles. Fifty RA patients with active disease (disease activity score in 28 joints (DAS28) >or=3.2), who started adalimumab therapy at 40 mg every other week, were included. At baseline, weeks 16 and 52 serum levels of MIF and lipids were assessed. In addition, the DAS28 and serum C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR) were determined. After 16 weeks of adalimumab therapy, both DAS28 and MIF levels were significantly decreased (p<0.001 and p = 0.020, respectively). This was sustained up to week 52 (p<0.001 and p = 0.012, respectively). CRP levels and ESR were significantly reduced after 16 and 52 weeks of adalimumab therapy (p<0.001). High-density lipoprotein cholesterol levels increased at week 16 (p<0.001), but returned to baseline at week 52. Apolipoprotein (apo) A-I levels increased at week 16 (p<0.001) and remained stable...Continue Reading

References

Jun 8, 2002·Atherosclerosis·Gérald LucUNKNOWN PRIME Study Group
Dec 20, 2002·Nature·Peter Libby
Sep 4, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Lena BrånénStefan Jovinge
Jul 7, 2005·Atherosclerosis·Calin PopaJos W M van der Meer
Apr 22, 2006·Nature Reviews. Drug Discovery·Eric F MorandJürgen Bernhagen
Dec 13, 2006·Annals of the Rheumatic Diseases·Lennart T H JacobssonPierre Geborek
Aug 19, 2007·Rheumatology·S I van LeuvenP P Tak

❮ Previous
Next ❯

Citations

May 13, 1998·Immunology Today·G OpdenakkerJ Van Damme
Mar 25, 2011·Future Medicinal Chemistry·Yousef Al-Abed, Sonya VanPatten
Dec 10, 2013·Arthritis Research & Therapy·Maria I RamosMaria C Lebre
Oct 19, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Barbara C OlendzkiRobert B Zurier
Apr 13, 2010·Clinical Rheumatology·Eduardo Nicolas PollonoMaria E Suarez-Almazor
Jun 15, 2011·Seminars in Arthritis and Rheumatism·Alper M van SijlMichael T Nurmohamed
Feb 28, 2015·Immunopharmacology and Immunotoxicology·Lorena Michele Brennan-BourdonJosé Francisco Muñoz-Valle
Apr 18, 2016·International Immunopharmacology·Tsuyoshi KasamaYusuke Miwa
May 20, 2015·Current Treatment Options in Neurology·Namrata Dhillon, Kimberly Liang
Oct 16, 2013·Atherosclerosis·D F van Breukelen-van der StoepM Castro Cabezas
Nov 12, 2016·Arthritis Research & Therapy·Shadi HassanDevy Zisman
Feb 17, 2017·International Journal of Rheumatic Diseases·Mahdi MahmoudiAhmad Reza Jamshidi
Jan 11, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael NurmohamedPaola Accossato
Feb 10, 2010·Nature Reviews. Rheumatology·Radjesh J BisoendialPaul Peter Tak
Feb 13, 2010·Expert Opinion on Therapeutic Targets·Dorothee GrevenRichard Bucala
Aug 10, 2019·Current Medical Research and Opinion·Addolorata CorradoFrancesco Paolo Cantatore
May 10, 2017·Clinical Rheumatology·C VlachopoulosD Tousoulis
Jun 12, 2020·Rheumatology International·Aliki I VenetsanopoulouAlexandros A Drosos
Mar 31, 2021·Expert Review of Proteomics·Anne C Bay-JensenClaus H Nielsen

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.